Depo-Provera meningioma lawsuits: July update on MDL 3140, Daubert, and the first trial date

If you are reading about the Depo-Provera lawsuits for the first time,
the court jargon can make the whole thing feel distant. MDL. Daubert.
Bellwether. Those words matter, but the basic question is much simpler:
did years of birth control shots play a part in a later meningioma
diagnosis?

That is the question now being fought in the federal Depo-Provera
litigation.

The federal cases are grouped in MDL No. 3140, In re: Depo-Provera
(Depot Medroxyprogesterone Acetate) Products Liability Litigation. The
case is in the Northern District of Florida before Judge M. Casey
Rodgers. The Judicial Panel on Multidistrict Litigation's July 1, 2026
pending MDL report lists the docket as 3:25-md-3140.

The case count has grown fast. A July 9 update from Lawsuit Information
Center reported 5,830 pending lawsuits in the Depo-Provera MDL. We are
treating that as a litigation update, not a court-certified final
number, because MDL counts move as new filings and transfers hit the
docket.

What does not change is the injury story we keep seeing: a woman used
Depo-Provera, Depo-SubQ Provera 104, or a generic depot
medroxyprogesterone acetate shot, then later learned she had a
meningioma. Meningiomas are often called benign tumors, but "benign" can
sound too soft. A tumor near the brain or spinal cord can still mean
surgery, radiation, vision issues, seizures, headaches, repeat MRIs,
missed work, and years of worry.

Why the June Daubert hearing matters

The court held Daubert hearings in late June. A Daubert hearing is not a
trial. No jury is deciding damages. The judge is deciding what expert
testimony is reliable enough to be heard later.

That matters because this litigation depends heavily on science.
Plaintiffs say prolonged exposure to medroxyprogesterone acetate can
increase the risk of intracranial meningioma. Pfizer and other
defendants are expected to push back on general causation, warning-label
issues, and whether any individual patient's tumor can fairly be tied to
the drug.

If the court allows the plaintiffs' experts to testify, the cases move
toward bellwether trials with a stronger path. If the court limits that
testimony, the litigation could look very different. We do not know the
final answer yet, and nobody should pretend otherwise.

The first bellwether trial is expected in December 2026, with litigation
updates pointing to a December 7 to 14 window. A bellwether is a test
case. It does not decide every person's claim. It does show both sides
how a jury reacts to the evidence.

The science people are talking about

The 2024 BMJ study is one reason these cases grew so quickly. PubMed
describes it as a national case-control study from France involving
women who had surgery for intracranial meningioma and matched controls.
The study looked at several progestogens, including medroxyprogesterone
acetate, and reported an increased association with prolonged use.

The FDA label changed too. The 2025 Depo-Provera CI prescribing
information lists "Warnings and Precautions, Meningioma" as a recent
major change dated December 2025. The label tells prescribers to
discontinue Depo-Provera CI if meningioma is diagnosed and to monitor
patients for signs and symptoms of meningioma.

Those two facts are important. They still do not prove every case. A
lawyer reviewing a claim will usually want to know when the shots
started, how many injections there were, when symptoms began, when
imaging found the tumor, and what treatment followed.

Who should consider asking questions

You may want a Depo-Provera meningioma case review if this sounds like
your history:

• You received Depo-Provera, Depo-SubQ Provera 104, or a generic depot medroxyprogesterone acetate injection.
• You used the shot more than once, especially over a longer period.
• A doctor diagnosed you with intracranial meningioma or spinal meningioma.
• You had surgery, radiation, ongoing scans, seizures, vision changes, headaches, or a recommendation for future treatment.

That is not a promise that you have a claim. It is a reason to have
someone look at the records. Some claims turn on small details,
including dates that may not be obvious until pharmacy and clinic
records are pulled.

Records that can help

Start with proof of the injections. Pharmacy histories, OB-GYN records,
clinic notes, insurance explanations of benefits, Medicaid records, and
patient portal summaries can all help. Depo-Provera is usually given
every three months, so a handful of dated visits may help rebuild the
timeline.

Then gather the diagnosis records. MRI reports, CT reports, neurosurgery
notes, pathology reports, hospital discharge papers, and radiation
oncology notes are especially useful. If all you have right now is a
screenshot from a portal, keep it. You can ask the imaging center or
hospital for the full report.

It also helps to write down what changed after the diagnosis. Did you
miss work? Stop driving for a while? Need help with childcare? Deal with
headaches, vision problems, balance issues, or repeat scans? A short
timeline written now is better than trying to remember everything a year
from now.

What we are watching next

We are watching for the court's rulings after the June Daubert hearings,
any orders about expert testimony, updated MDL counts, and the December
bellwether schedule.

We are also watching the settlement chatter carefully. Some legal sites
have reported movement around settlement discussions. That does not mean
there is a guaranteed payout, a set settlement value, or a result that
applies to every person. Case value depends on exposure proof,
diagnosis, treatment, age, damages, medical history, and the court's
rulings on the science.

If you used Depo-Provera and later received a meningioma diagnosis,
preserve your records and get case-specific advice. Do not stop or
change any medication because of something you read online. Talk with
your doctor about your symptoms, risks, and treatment options.

Attorney advertising. This article is general information, not medical
advice or legal advice. Reading it does not create an attorney-client
relationship. Prior results and litigation updates do not guarantee a
result in any specific case.

Sources checked

• Judicial Panel on Multidistrict Litigation, Pending MDLs as of July 1, 2026.
• JPML pending MDL docket by MDL number, listing MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers.
• Lawsuit Information Center, "Depo Provera Lawsuit Settlement | July 2026 Litigation Update," updated July 9, 2026.
• PubMed summary for "Use of progestogens and the risk of intracranial meningioma: national case-control study," BMJ 2024.
• FDA Depo-Provera CI prescribing information, 2025 label, including the December 2025 meningioma warning update.
• Pediatric Endocrine Society summary of the Depo-Provera FDA label update on meningioma risk.